<DOC>
	<DOC>NCT01604850</DOC>
	<brief_summary>This study was to assess the safety and efficacy of sofosbuvir in combination with ribavirin (RBV) administered for 12 or 16 weeks in participants with genotypes 2 or 3 hepatitis C virus (HCV) infection as assessed by the proportion of participants with sustained virologic response (SVR) 12 weeks after discontinuation of therapy (SVR12).</brief_summary>
	<brief_title>Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Infection with HCV genotype 2 or 3 Had cirrhosis determination Prior treatment failure Screening laboratory values within defined thresholds Subject had not been treated with any investigational drug or device within 30 days of the screening visit Use of highly effective contraception methods if female of childbearing potential or sexually active male Prior exposure to an directacting antiviral targeting the HCV nonstructural protein (NS)5B polymerase Pregnant or nursing female or male with pregnant female partner Current or prior history of clinical hepatic decompensation History of clinically significant illness or any other major medical disorder that may have interfered with subject treatment, assessment or compliance with the protocol Excessive alcohol ingestion or significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>HCV genotype 2 (GT-2)</keyword>
	<keyword>HCV genotype 3 (GT-3)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
</DOC>